No Data
No Data
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
RBC Capital Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $61
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)